Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasenra in Severe Eosinophilic Asthma
NCT07654842Phase 4Enrolling by invitation
- Sponsor
- Endeavor Health
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 4 trial of benralizumab in eosinophilic asthma (EA), sponsored by Endeavor Health. Started Jul 2026; status: enrolling by invitation.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT07654842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654842.